🟢 BioNTech is trading 6% up in pre-market after Phase 3 gotistobart trial showed survival benefit

BioNTech is trading 6.02% up now at $102.55 in pre-market after announcing positive Phase 3 results for gotistobart on September 14, 2026.

• Reuters reported a clinically meaningful overall-survival benefit, with survival nearly doubled versus standard chemotherapy in previously treated squamous non-small-cell lung cancer.
• Company-specific news outweighed weak pre-market conditions, with Nasdaq futures down 1.49%.